|ECR 2018 / C-3001|
|Transarterial Chemo-embolisation with degradable starch microspheres(DSM-TACE) in intermediate/advanced HCC patients dismissing or inelegible for Sorafenib|
A total of 86 treatments were performed. Technical success, defined as the ability to deliver the total planned dose or to obtain stop flow, was achieved in all patients. No intra- or peri-procedural complications occurred and in particular no signs of liver failure or systemic toxicity were detected. At 1-month follow-up, an objective response rate (ORR) of 45.9% and overall disease control (ODC) of 79.2% were observed. In nine patients with ODC and residual viable tumor higher than 50%, a repeated DSM-TACE treatment was performed. During the mean follow-up of 18.2 months an ODC of 45.8% was registered. PFS, calculated using the Kaplan-Meier method, was 5.8 months with a median OS of 10.8 months (Fig. 1; Fig.2).
When considering the subgroup evaluation (Fig.3), significant longer overall survival was obtained for BCLC-B intermediate Child-Pugh A patients compared with BCLC-C advanced Child-Pugh B patients. The outcome justifies the prognostic pivotal role of liver functional reserve in intermediate/advanced HCC patients with liver cirrhosis which has been previously described by other groups.
Thematically related posters
ECR 2018 / C-3043
Imaging features of hepatic malignancies during and after interventional radiological procedures: a practical guide for radiologists
ECR 2018 / C-1366
Transluminal biliary forceps biopsy: long term results from a single center experience